Eton Pharmaceuticals Received FDA Acceptance Of New Drug Application For ET-400
Portfolio Pulse from Benzinga Newsdesk
Eton Pharmaceuticals has received FDA acceptance for its New Drug Application (NDA) for ET-400. The Prescription Drug User Fee Act (PDUFA) target action date is set for February 28, 2025. The product has patent protection through 2043.
July 15, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eton Pharmaceuticals' NDA for ET-400 has been accepted by the FDA, with a PDUFA target action date of February 28, 2025. The product has patent protection through 2043.
The acceptance of the NDA by the FDA is a significant milestone for Eton Pharmaceuticals, indicating potential future revenue from ET-400. The PDUFA date provides a clear timeline for investors, and the long-term patent protection adds value to the product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100